NewAmsterdam Pharma Company NV has outlined its strategic priorities for 2026, which include preparing for the potential commercial launch of obicetrapib and its fixed-dose combination with ezetimibe in Europe, subject to European Medicines Agency $(EMA)$ approval expected in the second half of 2026. The company is advancing its cardiovascular outcomes trial, PREVAIL, and has initiated the RUBENS Phase 3 trial to evaluate obicetrapib and its fixed-dose combination in patients with metabolic syndrome. NewAmsterdam aims to achieve topline results from the RUBENS trial by the end of 2026 and is exploring the potential for additional label enhancements for patients with Type 2 Diabetes and/or Metabolic Syndrome who are not meeting LDL-C risk-based goals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622745-en) on January 09, 2026, and is solely responsible for the information contained therein.